This Painkiller Gives Rivals A HeadacheZachary Schiller
FIREWORKS WERE EXPECTED when Procter & Gamble's new Aleve muscled into the $2.6 billion painkiller market. No one was disappointed. Aleve, an over-the-counter version of prescription drug Anaprox, was rolled out in June with TV ads claiming it lasts longer than market leader Tylenol and, by implication, other remedies. Since its debut, according to independent data made public by P&G, Aleve had powered into a tie with Excedrin for third place among brand names (chart).
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Bitcoin Futures Deliver Wild Ride as Debut Brings Rally, Halts
- Investors Told to Brace for Steepest Rate Hikes Since 2006
- A Manager of $42 Billion Fears Bubble in World's Biggest Stocks
- Longtime NPR Host Tom Ashbrook Is Facing Misconduct Allegations
- Buffett's About to Get $3 Billion Back From Burger King Owner